LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.03 -6.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.03

Max

1.13

Põhinäitajad
By Trading Economics
Sissetulek	3.6M -34M
Müük	278K 1.9M
Kasumimarginaal	-1,786.576
Töötajad	181
EBITDA	979K -37M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+312.84% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. nov 2025

Turustatistika
By TradingEconomics
Turukapital	38M 145M
Eelmine avamishind	7.39
Eelmine sulgemishind	1.03

Uudiste sentiment

By Acuity

80%

20%

346 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. nov 2025, 23:38 UTC

Tulu

OCBC Posts Steady Third-Quarter Net Profit, Drop in Net Interest Income

6. nov 2025, 23:00 UTC

Tulu

Macquarie's First-Half Profit Grows 2.7%, Missing Forecasts -- Update

6. nov 2025, 22:19 UTC

Tulu

Suurimad hinnamuutused turgudel

Block Shares Slide After 3Q Results Miss Estimates

6. nov 2025, 21:53 UTC

Tulu

Macquarie's First-Half Profit Grows 2.7%, Missing Forecasts

6. nov 2025, 23:45 UTC

Tulu

Wheaton Precious Metals 3Q Sales $476M >WPM

6. nov 2025, 23:45 UTC

Tulu

Wheaton Precious Metals 3Q Adj EPS 61.8c >WPM

6. nov 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. nov 2025, 23:45 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stocks Drop

6. nov 2025, 23:45 UTC

Tulu

Wheaton Precious Metals 3Q EPS 80.7c >WPM

6. nov 2025, 23:38 UTC

Market Talk

Gold Edges Higher Amid Worrisome Signs for U.S. Economy -- Market Talk

6. nov 2025, 23:15 UTC

Tulu

Kakao 3Q Net Profit Beat FactSet-Compiled Consensus

6. nov 2025, 23:14 UTC

Tulu

Kakao 3Q Net KRW192.86B Vs. Net KRW78.51B >035720.SE

6. nov 2025, 23:14 UTC

Tulu

Kakao 3Q Oper Pft KRW208.05B Vs. Pft KRW130.53B >035720.SE

6. nov 2025, 23:13 UTC

Tulu

Kakao 3Q Rev KRW2.087T Vs. KRW1.921T >035720.SE

6. nov 2025, 23:08 UTC

Tulu

Oversea-Chinese Banking Corp. 3Q Total Income S$3.80B Vs. S$3.80B >O39.SG

6. nov 2025, 23:08 UTC

Tulu

Oversea-Chinese Banking Corp. 3Q Noninterest Income S$1.57B Vs. S$1.37B >O39.SG

6. nov 2025, 23:07 UTC

Tulu

Oversea-Chinese Banking Corp. 3Q Net S$1.98B Vs. Net S$1.97B >O39.SG

6. nov 2025, 23:07 UTC

Tulu

Suzano 3Q Rev BRL12.2B >SUZ

6. nov 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

Wheaton Precious Metals to Pay Waterton Gold $670M Up Front

6. nov 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

Wheaton Precious Metals to Buy Gold Stream on Spring Valley Project Located in Nevada >WPM

6. nov 2025, 22:45 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific and Norfolk Southern Provide Supplemental Disclosures to Joint Proxy Statement About Merger

6. nov 2025, 22:25 UTC

Omandamised, ülevõtmised, äriostud

At Bank of America's Investor Day, M&A Hints, Would-Be CEOs, and AI Pitches -- Barrons.com

6. nov 2025, 22:13 UTC

Tulu

Fairfax Financial 3Q Rev $8.27B >FFH.T

6. nov 2025, 22:02 UTC

Tulu

Century Aluminum 3Q Sales $632.2M >CENX

6. nov 2025, 22:02 UTC

Tulu

Century Aluminum 3Q Adj EPS 56c >CENX

6. nov 2025, 21:53 UTC

Tulu

DraftKings Stock Sinks on Disappointing Results -- Barrons.com

6. nov 2025, 21:52 UTC

Omandamised, ülevõtmised, äriostud

Universal Display: Portfolio Includes More Than 300 Issued and Pending Patents Worldwide, Covering More Than 110 Unique Patent Families >OLED

6. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Universal Display Corp to Acquire Emissive OLED Patent Assets From Merck KGaA, Darmstadt, Germany

6. nov 2025, 21:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

6. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

312.84% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD 312.84%

Kõrge 7 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

346 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.